The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial

Table 4 Adverse and serious adverse events

Placebo	IL-1Ra
Fluctuating GCS	Raised ICP; hypotension^a
Desaturation; cardiac arrhythmia; meningitis	Chest sepsis; focal seizures cardiac arrhythmia; increased urine output; increased CRP^a
IV line infection; chest infection; focal seizure	Ventilator-associated pneumonia
Leaking wound^a
Acute agitation^a; pyrexia of unknown origin^a

^aThe 18 adverse and serious adverse events are shown for the five participants that received placebo and the three that received IL-1Ra, in whom they occurred. CRP, C-reactive protein; GCS, Glasgow Coma Scale; ICP, intracranial pressure; IL-1Ra, interleukin-1 receptor antagonist; IV, intravenous.

ISSN: 1742-2094